ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,184,403 | +372.2% | 1,160,480 | +442.6% | 0.01% | – |
| Q2 2023 | $5,122,019 | -26.1% | 213,863 | -41.9% | 0.00% | -100.0% |
| Q1 2023 | $6,926,889 | +144.9% | 368,060 | +107.2% | 0.00% | – |
| Q4 2022 | $2,827,997 | -57.8% | 177,638 | -56.6% | 0.00% | -100.0% |
| Q3 2022 | $6,699,000 | -40.3% | 409,490 | -48.6% | 0.00% | -66.7% |
| Q2 2022 | $11,222,000 | -42.7% | 796,413 | -1.5% | 0.00% | 0.0% |
| Q1 2022 | $19,586,000 | -65.4% | 808,683 | -66.6% | 0.00% | +50.0% |
| Q4 2021 | $56,554,000 | +381.6% | 2,423,040 | +242.7% | 0.00% | 0.0% |
| Q3 2021 | $11,744,000 | -53.9% | 707,040 | -32.4% | 0.00% | -50.0% |
| Q2 2021 | $25,492,000 | -32.3% | 1,045,174 | -28.4% | 0.00% | -33.3% |
| Q1 2021 | $37,663,000 | -37.5% | 1,459,816 | +29.5% | 0.01% | +50.0% |
| Q4 2020 | $60,272,000 | +131.5% | 1,127,438 | +78.6% | 0.00% | -20.0% |
| Q3 2020 | $26,034,000 | -16.0% | 631,122 | -1.3% | 0.01% | -37.5% |
| Q2 2020 | $30,990,000 | +76.2% | 639,373 | +53.6% | 0.01% | +60.0% |
| Q1 2020 | $17,590,000 | -66.5% | 416,333 | -66.1% | 0.01% | -68.8% |
| Q4 2019 | $52,462,000 | +9.1% | 1,226,319 | -8.2% | 0.02% | 0.0% |
| Q3 2019 | $48,103,000 | -49.8% | 1,336,572 | -62.7% | 0.02% | +33.3% |
| Q2 2019 | $95,849,000 | +210.1% | 3,585,841 | +211.5% | 0.01% | -7.7% |
| Q1 2019 | $30,913,000 | +9.1% | 1,151,295 | -34.3% | 0.01% | +8.3% |
| Q4 2018 | $28,347,000 | -25.0% | 1,753,108 | -3.7% | 0.01% | 0.0% |
| Q3 2018 | $37,794,000 | +193.4% | 1,820,500 | +115.8% | 0.01% | +140.0% |
| Q2 2018 | $12,881,000 | -68.9% | 843,500 | -54.2% | 0.01% | -64.3% |
| Q1 2018 | $41,421,000 | +20.8% | 1,843,400 | +61.9% | 0.01% | +27.3% |
| Q4 2017 | $34,277,000 | -37.3% | 1,138,386 | -21.6% | 0.01% | -47.6% |
| Q3 2017 | $54,702,000 | +74.0% | 1,452,137 | +28.8% | 0.02% | +61.5% |
| Q2 2017 | $31,446,000 | -54.4% | 1,127,518 | -43.8% | 0.01% | -62.9% |
| Q1 2017 | $69,002,000 | +8.5% | 2,007,025 | -9.0% | 0.04% | +9.4% |
| Q4 2016 | $63,609,000 | +16.2% | 2,205,560 | +28.2% | 0.03% | +18.5% |
| Q3 2016 | $54,737,000 | -10.8% | 1,720,757 | -8.9% | 0.03% | -15.6% |
| Q2 2016 | $61,337,000 | -9.7% | 1,889,603 | -22.2% | 0.03% | -13.5% |
| Q1 2016 | $67,937,000 | -1.2% | 2,429,797 | +26.0% | 0.04% | +15.6% |
| Q4 2015 | $68,753,000 | +22.9% | 1,928,547 | +14.0% | 0.03% | +33.3% |
| Q3 2015 | $55,933,000 | -0.2% | 1,691,379 | +26.4% | 0.02% | 0.0% |
| Q2 2015 | $56,021,000 | +9.9% | 1,337,677 | -14.5% | 0.02% | +4.3% |
| Q1 2015 | $50,985,000 | -14.3% | 1,564,455 | -16.5% | 0.02% | -4.2% |
| Q4 2014 | $59,478,000 | +27.2% | 1,873,301 | -0.8% | 0.02% | +33.3% |
| Q3 2014 | $46,770,000 | -5.2% | 1,888,936 | -13.5% | 0.02% | -14.3% |
| Q2 2014 | $49,328,000 | -3.6% | 2,183,628 | +3.9% | 0.02% | -12.5% |
| Q1 2014 | $51,155,000 | +13.6% | 2,102,593 | +16.6% | 0.02% | +14.3% |
| Q4 2013 | $45,046,000 | -9.7% | 1,802,573 | -0.8% | 0.02% | -19.2% |
| Q3 2013 | $49,893,000 | +67.1% | 1,816,284 | +10.4% | 0.03% | +62.5% |
| Q2 2013 | $29,855,000 | – | 1,644,926 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |